Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy

Agnes Bonifacius1, Sabine Tischer-Zimmermann1, Maria Michela Santamorena1, Philip Mausberg1, Josephine Schenk1, Stephanie Koch2, Johanna Barnstorft-Brandes1, Nina Gödecke1, Jörg Martens1, Lilia Goudeva1, Murielle Verboom1, Jana Wittig3,4 Britta Maecker-Kolhoff3, Herrad Baumann6, Caren Clark6, Olaf Brauns6, Martina Simon6, Peter Lang7, Oliver A. Cornely3,4,8,9, Michael Hallek3, Rainer Blasczyk1, Dominic Seiferling10, Philipp Köhler3,4 and Britta Eiz-Vesper1*

1Hannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany, 2Deutsche Gesellschaft für Gewebetransplantation, Hannover, Germany, 3Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany, 4Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany, 5Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany, 6Mittenny Biotec B.V. & Co. KG, Bergisch Gladbach, Germany, 7Department of Pediatric Hematology and Oncology, University Children’s Hospital, University of Tuebingen, Tuebingen, Germany, 8Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany, 9German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany, 10Mittenny Biomedicine GmbH, Bergisch Gladbach, Germany

Objectives: Evaluation of the feasibility of SARS-CoV-2-specific T cell manufacturing for adoptive T cell transfer in COVID-19 patients at risk to develop severe disease.

Methods: Antiviral SARS-CoV-2-specific T cells were detected in blood of convalescent COVID-19 patients following stimulation with PepTivator SARS-CoV-2 Select using Interferon-gamma Enzyme-Linked Immunospot (IFN-γ ELISpot), SARS-CoV-2 T Cell Analysis Kit (Whole Blood) and Cytokine Secretion Assay (CSA) and were characterized with respect to memory phenotype, activation state and cytotoxic potential by multicolor flow cytometry, quantitative real-time PCR and multiplex analyses. Clinical-grade SARS-CoV-2-specific T cell products were generated by stimulation with MACS GMP PepTivator SARS-CoV-2 Select using CliniMACS Prodigy and CliniMACS Cytokine Capture System (IFN-gamma) (CCS). Functionality of enriched T cells was investigated in cytotoxicity assays and by multiplex analysis of secreted cytotoxic molecules upon target recognition.

Results: Donor screening via IFN-γ ELISpot allows for pre-selection of potential donors for generation of SARS-CoV-2-specific T cells. Antiviral T cells reactive against PepTivator SARS-CoV-2 Select could be magnetically enriched from peripheral blood of convalescent COVID-19 patients by small-scale CSA resembling the clinical-grade CCS manufacturing process and showed an activated and cytotoxic T cell phenotype. Four clinical-grade
SARS-CoV-2-specific T cell products were successfully generated with sufficient cell numbers and purities comparable to those observed in donor pretesting via CSA. The T cells in the generated products were shown to be capable to replicate, specifically recognize and kill target cells in vitro and secrete cytotoxic molecules upon target recognition. Cell viability, total CD3+ cell number, proliferative capacity and cytotoxic potential remained stable throughout storage of up to 72 h after end of leukapheresis.

**Conclusion:** Clinical-grade SARS-CoV-2-specific T cells are functional, have proliferative capacity and target-specific cytotoxic potential. Their function and phenotype remain stable for several days after enrichment. The adoptive transfer of partially matched, viable human SARS-CoV-2-specific T lymphocytes collected from convalescent individuals may provide the opportunity to support the immune system of COVID-19 patients at risk for severe disease.

**Keywords:** adoptive T cell therapy, antiviral T cells, immunotherapy, SARS-CoV-2, COVID-19

**INTRODUCTION**

Despite the approval of several vaccines against SARS-CoV-2, there is a high medical need for further therapeutic options to facilitate convalescence from the infection and prevent a severe course of the disease. Early treatment strategies for COVID-19 patients include immunomodulatory approaches such as dexamethasone, antiviral substances such as remdesivir, antimalarial drugs, and monoclonal antibodies or convalescent plasma (COVID-19 Treatment Guidelines Panel, 2021). The appearance of new variants (variant of concern, VOC) calls for new therapeutic strategies as increased clinical severity of COVID-19 and even vaccine evasion may pose additional problems (World Health Organisation, 2021). Especially the efficacy of treatment with convalescent plasma is in question since the target of neutralizing antibodies, the receptor-binding domain (RBD) is increasingly mutated in VOCs and immune escape variants may emerge (Cameroni et al., 2021; Focosi et al., 2021; Wang et al., 2022). Recently, the antiviral drugs Molnupiravir (Lagevrio) and Nirmatrelvir (Paxlovid), inhibiting viral replication, have been authorized for treatment of COVID-19 by the FDA1,2 while the European Medicines Agency is currently evaluating their marketing authorization application3. However, these drugs have to be administered at very early time point of infection and come with potentially severe side effects, therefore their application has to be carefully evaluated and is limited to patients at risk for severe disease. Moreover, data regarding the antiviral effect of Nirmatrelvir on Omicron variant (B.1.1.529) are not yet available. During SARS-CoV-2 infection and subsequent recovery, SARS-CoV-2-specific T cells emerge as part of the adaptive immune response mediating control of infected cells, viral clearance, and possibly long lasting protective immunity (Chen and John Wherry, 2020; Bertoletti et al., 2021; Pilz et al., 2022).

Throughout recovery and convalescence, significant numbers of SARS-CoV-2-specific memory T cells reactive against Spike (S), Nucleocapsid (N), and Membrane (M) proteins of SARS-CoV-2 are detectable (Peng et al., 2020; Bonifacius et al., 2021). Particularly in convalescent individuals recovering from mild or even asymptomatic disease, a robust, broad and highly functional T cell response can be detected suggesting effective protection from SARS-CoV-2 reinfection (Bonifacius et al., 2021; Gussarov et al., 2021; Le Bert et al., 2021; Marcotte et al., 2022). In contrast to neutralizing antibodies, antiviral T cells developed during SARS-CoV-2 infection with wild type or earlier VOCs, were shown to efficiently recognize antigens from Omicron variant (Gao et al., 2022). On the other hand, some patients do not mount an appropriate, efficient T cell reaction but exhibit inadequate immune responses (Jarjour et al., 2021). Patients with severe COVID-19 generally develop lymphopenia, disruption of the T cell compartment, and CD8+ memory T cell exhaustion (Bacher et al., 2020; He et al., 2021; Vigón et al., 2021). Reduced T cell counts and an increased granulocyte to lymphocyte ratio correlate with disease severity and are early predictive markers of an adverse course (Kong et al., 2020; Liu et al., 2020). In patients with severe and advanced disease, misled innate and adaptive immune cells can cause a hyperinflammatory state, often resulting in endothelial inflammation, hypercoagulation, and end-organ damage (Garcia, 2020). The adoptive transfer of SARS-CoV-2-specific T cells isolated from convalescent individuals might therefore support the patient’s immune system allowing protective T cell immunity to be restored and subsequent viral clearance in these patients (Hanley et al., 2020).

The concept of adoptive T cell therapy has been developed for viral infections in immunosuppressed patients after allogeneic stem cell (HSCT) and solid organ transplantation (SOT). Refractory viral infections due to Cytomegalovirus (CMV), Adenovirus (AdV), and Epstein-Barr virus (EBV) after HSCT

---

1https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain.
2https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19.
3https://www.ema.europa.eu/en/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-covid-19/covid-19-treatments-under-evaluation#covid-19-treatments-under-marketing-authorisation-evaluation-section.
represent life-threatening conditions due to the insufficient endogenous T cell response of the recipient and lack of effective treatment options. However, the concept of adoptive T cell therapy not only applies to patients with transplantation history but also to those generally immunocompromised due to a variety of underlying diseases. In detail, progressive multifocal leukoencephalopathy (PML), caused by reactivation of JC polyomavirus (JCV), occurs in immunocompromised patients, and is associated with high morbidity and mortality mainly because there are no targeted therapies available (Brew et al., 2010; Cortese et al., 2021). Hence, the reconstitution of T cell immunity by adoptive transfer of virus-specific T cells is a promising approach (Muftuoglu et al., 2018; Steinhardt et al., 2020; Berzero et al., 2021; Hopfner et al., 2021).

The repertoire of SARS-CoV-2-specific T cells in COVID-19 patients convalescent from mild disease covers a broad range of viral antigens including antigens from different VOCs. In contrast, in the majority of hospitalized patients reduced functionally active antiviral T cells are observed (Bergamaschi et al., 2021; Bonifacius et al., 2021; He et al., 2021). Adoptive transfer of virus-specific T cells in different settings appears safe and effective (Withers et al., 2017). It therefore can be hypothesized that the transfusion of viable donor-derived SARS-CoV-2-specific T cells collected from convalescent individuals will support the immune systems of individuals at risk during an early course of the disease (Hanley et al., 2020). Due to the possibility of rapid deterioration of the patient, quick turnaround times in production, and logistics of T cell substances are mandatory. The CliniMACS Cytokine Capture System (CCS) IFN-gamma allows for rapid generation of antiviral T cell products in sufficient number and purity within 16 h after leukapheresis using CliniMACS Prodigy instrument. Moreover, since the SARS-CoV-2-specific peptide pool PepTivator SARS-CoV-2 Select contains peptides derived from structural as well as non-structural proteins and since the majority of these epitopes are identical between wild type SARS-CoV-2 and circulating VOCs, antiviral T cell products generated using PepTivator SARS-CoV-2 Select display a broad antigenic specificity covering epitopes from both, wild type SARS-CoV-2 and VOCs. By screening the mutations of the currently circulating VOCs we found in Alpha 1-, in Delta 2- and in the Omicron subtype 5 out of 88 peptides of the PepTivator SARS-CoV-2 Select being affected by amino acid mutations of the respective Virus subtype4. Thus, even the currently circulating Omicron variant with the highest number of mutations in different proteins is matched by > 90% of peptides contained in PepTivator SARS-CoV-2 Select. Three out of five affected peptides of the PepTivator SARS-CoV-2 Select are solely altered in their periphery when compared to the Omicron Virus subtype sequence, suggesting that these peptides will still be presented on the respective HLA alleles. Moreover, the HLA subtypes represented by these peptides (e.g., A*24, DRB1*04:04, and DRB1*15:01) are covered by several other peptides, too. Two out of five peptides are found to be affected in their core region, which might influence the binding capability to the respective HLA alleles. A matching between patient and donor based only on these HLA alleles (B*27, DQB1*04) should therefore be avoided. Taken together, by adoptive transfer of human SARS-CoV-2-specific T cells isolated from convalescent individuals using MACS GMP PepTivator SARS-CoV-2 Select the protective T cell immunity in patients suffering from COVID-19 could be restored and may thereby prevent a severe course of the disease.

MATERIALS AND METHODS

Convalescent COVID-19 Patients

The study was approved by the Internal Review Board of Hannover Medical School (MHH, approval number 3639_2017, 9001_BO-K, 9255_BO_K_2020). All 198 donors (n = 90 male, n = 108 female) aged 18–69 years (mean 41 years) were recruited from MHH between October 2020 and July 2021. Convalescent COVID-19 patients with confirmed history of SARS-CoV-2 infection were sampled up to 61 weeks after symptom onset and at least 2 weeks after negative PCR.

Determination of Antiviral T Cells by ELISpot Assay

Virus-specific T lymphocytes were detected by Interferon-gamma (IFN-γ) Enzyme-Linked Immunospot (ELISpot) Assay as previously described (Bieling et al., 2018). Briefly, Peripheral Blood Mononuclear Cells (PBMC) were isolated from blood samples by discontinuous density gradient centrifugation, resuspended in culture medium consisting of RPMI-1640 (Lonza, Verviers, and Belgium) supplemented with 10% human AB serum (C.C.pro, Oberdorla, and Germany) at a concentration of 1 × 10^7 cells/ml, seeded in 24-well plates and rested overnight. For retrospective analyses, PBMCs were frozen and stored at −70°C until thawing and overnight resting prior to ELISpot assay. Rested PBMCs were cultured in anti-IFN-γ pre-coated ELISpot plates (Lophius Biosciences, Regensburg, and Germany) for 16–18 h at a density of 2.5 × 10^3 cells/well in presence of PepTivator SARS-CoV-2 membrane (M), nucleoprotein (N) or Select (Milenyi Biotec, Bergisch Gladbach, Germany) or PepMix SARS-CoV-2 Spike (S) protein from wild type, Delta or Omicron VOC (JPT Peptide Technologies, Berlin, Germany) at a final concentration of 1 µg of each peptide/ml. PepTivator SARS-CoV-2 Select consists of 88 peptides with a length of 9–22 amino acids originating from structural and non-structural proteins. The peptides are restricted to Major Histocompatibility (MHC) class I (n = 63 peptides), covering n = 19 frequent Human Leukocyte Antigen (HLA) alleles, and MHC class II (n = 25), covering n = 6 frequent HLA alleles. Cells stimulated with staphylococcal enterotoxin B (1 µg/ml, SEB, Merck, Taufkirchen, Germany) served as positive controls, and PBMCs incubated in media alone as negative controls (NC). IFN-γ secretion was detected using streptavidin-alkaline phosphatase (Mabtech Stockholm, Sweden) and revealed by 5–13 bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium (BCIP/NBT Liquid Substrate, Merck, Darmstadt, Germany). Spots were counted using AID ELISPOT 8.0 on an AID iSpot spectrum reader system (both from AID, Strassberg, and Germany). Means of duplicate well readings were calculated and expressed.

---

4https://outbreak.info/situation-reports.
as the number of spots per well (spw). The threshold for a response was set at 2xNC+1 or ≥3.

Characterization of Antiviral T Cells by Whole Blood Assay

The SARS-CoV-2 T Cell Analysis Kit (Whole Blood) (Miltenyi Biotec) was performed according to the manufacturer’s instructions. In brief, heparinized whole blood was filled into 48 well plates (1 ml/well) and stimulated with PepTivator SARS-CoV-2 Select (1 µg of each peptide/ml) for 8 h. Unstimulated samples served as negative control and samples stimulated with CytoStim (Miltenyi Biotec) served as positive control. Cytokine secretion was blocked by supplementation with Brefeldin A (Miltenyi Biotec). After a total of 8 h of stimulation, erythrocytes were lysed (Red Blood Cell Lysis Solution; Miltenyi Biotec), samples were fixed, and permeabilized followed by staining with the following antibodies: anti-CD3 Allophycocyanin (APC), anti-CD4 Vio Bright B515, anti-CD8 VioGreen, anti-IFN-γ Phycoerythrin (PE), anti-Tumor Necrosis Factor alpha (TNF-α) PE-Vio 770, anti-CD20 VioBlue, and anti-CD154 APC-Vio 770 (all Miltenyi Biotec). Samples were acquired on a MACSQuant Analyzer 10 (Miltenyi Biotec).

Detection and Enrichment of Antiviral T cells by IFN-γ Cytokine Secretion Assay

The IFN-γ cytokine secretion assay (CSA, Miltenyi Biotec) was performed as previously described (Tischer et al., 2014a). After overnight resting in TexMACS Medium (Miltenyi Biotec), 1 × 10⁷ isolated PBMCs were stimulated with PepTivator SARS-CoV-2 Select (Miltenyi Biotec) at a final concentration of 1 µg of each peptide/ml peptide pool. Unstimulated PBMCs served as negative controls. Activated IFN-γ-secreting T cells were specifically captured during the magnetic enrichment process using anti-IFN-γ-PE antibodies and paramagnetic anti-PE microbeads. Aliquots of the respective cell fractions collected before (pre drug substance (preDS)) and after enrichment (DS) were used for analysis of IFN-γ T cell subsets by multicolor flow cytometry. Dead cells were excluded from analysis by 7-amino-actinomycin D (7-AAD) staining (BD Biosciences, Heidelberg, Germany). The percentage of viable IFN-γ+ cells was determined by staining the cells with anti-CD45 APC-H7, anti-CD3 Fluorescein Isothiocyanate (FITC), anti-CD8 APC, and anti-CD4 Alexa Fluor 700 (AF700) mAbs (all from BD Biosciences). At least 10,000 events were acquired in the viable CD45+ leukocyte gate in each test (system: FACSCanto10c, BD Biosciences, Heidelberg, Germany). CD3+/IFN-γ+, CD8+/IFN-γ- and CD4+/IFN-γ+ T cell populations were gated based on the scatter properties of viable 7-AAD+/CD45+CD3+ T cells. Moreover, for selected donors, the activation state of the cells was analyzed by staining the cells with anti-CD45 Pacific Blue, anti-CD3 FITC, anti-CD8 APC, anti-CD4 AF700, anti-CD14 BV510, anti-CD19 BV510, anti-CD69 BV605, anti-CD137 PE-Cyanine 7 (PE-Cy7), and anti-CD154 APC-Cy7 mAbs (BD Biosciences and BioLegend). Dead cells were excluded from analysis by 7-AAD staining (BD Biosciences). The following gating strategy was applied: CD45+7-AAD SSClowCD3+CD14+19’ (CD3+ T cells), CD45+7-AAD SSClowCD3+CD14+19’/CD8+ (CD8+ T cells), and CD45+7-AAD SSClowCD3+CD14+19’/CD4+ (CD4+ T cells). The following acceptance criteria apply for donation of SARS-CoV-2-specific T cells for clinical application: CD3⁺/IFN-γ⁺ pre-enrichment ≥ 0.01% or enrichment of a clear, defined population of ≥10% CD3⁺/IFN-γ⁺.

Gene Expression Analysis by Quantitative Real-Time PCR (qRT-PCR)

Messenger RNA (mRNA) amounts of IFN-γ, perforin and granzyme B were analyzed as previously described (Bunse et al., 2015). Briefly, total cellular RNA (RNasey Mini Kit; QIAGEN, Hilden, Germany) was isolated from SARS-CoV-2-specific T cells magnetically enriched via CSA (see above) or unstimulated control cells. The cDNA was amplified using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Darmstadt, and Germany). mRNA amounts were quantified using inventoried mixes and TaqMan Gene Expression Master Mix (both from Applied Biosystems). Constitutively expressed glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as the reference gene. All tests were performed in duplicates.

Clinical Grade Manufacturing of SARS-CoV-2-specific T Cells

In n = 4 clinical-grade manufacturing processes, SARS-CoV-2-specific T cells were isolated from leukapheresis products (LP) of pretested COVID-19-recoved donors using the CliniMACS Prodigy device (Miltenyi Biotec) and the CliniMACS CCS IFN-gamma (Miltenyi Biotec) following the manufacturer’s written instructions. In brief, total nucleated cell numbers in the LP were measured (Coulter ACTdiff, Beckman Coulter, Krefeld, Germany) and the process was initiated using 1 × 10⁹ total nucleated cells. The following steps were carried out autonomously by the CliniMACS Prodigy device: ex vivo restimulation (4 h, 37°C, 5% CO₂) with MACS GMP PepTivator SARS-CoV-2 Select (1 µg/ml per peptide, Miltenyi Biotec), labeling of white blood cells with the CliniMACS CCS Catchmatrix Reagent (37°C, 5% CO₂), secretion phase, labeling and immunomagnetic separation of IFN-γ-secreting cells by antibody-conjugated super-paramagnetic particles (CliniMACS IFN-γ Enrichment Reagent, Miltenyi Biotec). Prior to immunomagnetic separation, a quality control sample (preDS) was taken from the quality control bag.

Quality Control of Clinical-Grade SARS-CoV-2-specific T Cell Products

Quality control of LP, preDS, and DS was performed as previously described (Tischer et al., 2014b). Total CD45⁺ leukocytes, viability, and frequencies as well as total cell numbers were determined using Trucount Absolute Counting Tubes (BD Biosciences) and the following staining reagents: anti-
CD45 APC-H7 and anti-CD3 FITC mAbs and 7-AAD (all BD Biosciences). After staining, erythrocytes were lysed using Lysing Solution (Beckman Coulter) and samples were acquired on a BD FACSCanto 10c with at least 10,000–50,000 events in the Trucount beads gate. Purity, memory phenotype and cellular composition were analyzed using combinations of the following staining reagents: anti-CD45 APC-H7, anti-CD3 FITC, anti-CD4 AF700, anti-CD8 APC, anti-CD14 BV510, anti-CD19 BV510, anti-IFN-γ PE, anti-CD45RA BV605, anti-CD62L BV421, anti-CD56 AF700, anti-CD33 APC, anti-CD19 PE-Cy7 mAbs, and 7-AAD (all BD Biosciences). After staining and lysis of erythrocytes, samples were acquired on a BD FACSCanto 10c with at least 10,000–50,000 events in the CD45+ leukocyte gate.

Expansion of CCS-Enriched SARS-CoV-2-specific T Cells
SARS-CoV-2-specific T cells enriched via CCS using the CliniMACS Prodigy device and MACS GMP PepTivator SARS-CoV-2 Select (Miltenyi Biotec) were seeded into 24 well plates at 1 × 10^5 cells per well in TexMACS (Miltenyi Biotec). For feeder cells, autologous PBMCs were irradiated at 50 Gy and seeded at 1 × 10^5 cells per well. Cultures were supplemented with recombinant human Interleukin-2 (rhIL-2, 50 IU/ml; Miltenyi Biotec) and maintained for 7–13 days including regular media change and splitting of the cells.

Cytotoxicity Assay
Autologous PBMCs were labeled using the CellTrace Violet Cell Proliferation Kit (Invitrogen, Waltham, MS United States), seeded into 24 well plates and loaded with PepTivator SARS-CoV-2 Select overnight. Unloaded PBMCs served as control for unspecified killing. Expanded T cells were harvested, counted and seeded into 96 well plates together with unloaded or loaded PBMCs in different effector-to-target ratios (1:1, 2:1, 5:1, and 10:1). As a control for target cell viability, target cells were incubated in absence of T cells. CellEvent Caspase 3/7 Detection Reagent (Invitrogen) was added to the cultures. After 4 hours, supernatants were collected for subsequent multiplex analysis. Cells were washed and stained with 7-AAD and analyzed via flow cytometry using the BD FACSCanto 10c system.

Cytokine/Chemokine Measurement in Cell Culture Supernatant
Cell culture supernatants collected from cytotoxicity assays were subjected to LEGENDPlex using the CD8/NK Cell Kit (BioLegend). Samples were prepared and acquired using the BD FACSCanto 10c system according to the manufacturer’s instruction.

Data Analysis
Data were analyzed using BD FACSDiva v8.0.1 (BD Biosciences), FlowJo v10 (FlowJo LLC, BD Biosciences), LEGENDPlex Software (v8.0), and Microsoft Excel 2010 (Microsoft Corporation, Redmond). Prism Version 8.2.0 (GraphPad Software, San Diego, United States) was used to generate graphs as well as for statistical analysis using a linear regression model and the Kruskal–Wallis or Friedman test followed by multiple comparison correction. Significance levels were calculated and expressed as p-values (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).

RESULTS
Donor Screening and Pretesting for SARS-CoV-2-specific T Cells
Convalescent COVID-19 donors (n = 198) were analyzed first with regard to antiviral T cell frequencies via IFN-γ ELISpot Assay using PepTivator SARS-CoV-2 Select (Figure 1A). SARS-CoV-2-specific T cells were detectable in n = 104/198 donors (52.5%) with a median frequency of 10.75 spw/2.5 × 10^5 PBMCs (responders only). To further characterize the antiviral T cells, IFN-γ and TNF-α-producing T cells were detected in heparinized whole blood (Figure 1B). T cells responding to PepTivator SARS-CoV-2 Select were mainly multifunctional CD8+ and CD4+ cells producing IFN-γ and/or TNF-α (mean: CD8+ 0.06%; CD4+ 0.05% (cumulative), values from unstimulated control were subtracted).

In perspective of generation of SARS-CoV-2-specific T cells for clinical application, IFN-γ-secreting cells were detected and magnetically enriched via CSA (Figure 1C), representing the small-scale process largely analogous to the clinical large-scale CCS manufacturing process. In all tested donors (n = 22), SARS-CoV-2-specific T cells were detectable, with pre-enrichment frequencies of CD3+/IFN-γ+ cells ranging from 0.01 to 0.18% (mean 0.07%). Comparing the results obtained by ELISpot Assay and CSA, trends for a positive correlation were found between antiviral T cells detected by ELISpot Assay and frequencies of CD3+/IFN-γ+ cells both, pre-enrichment (corresponding to "preDS" in clinical-grade manufacturing) and post-enrichment (corresponding to "DS" in clinical manufacturing) (Figure 1D).

The mean purity obtained after magnetic enrichment was 37.44% (3.17–76.08%, Figure 1D). From the n = 22 donors tested, n = 18 fulfilled the acceptance criteria for donation of SARS-CoV2-specific T cells for clinical application (CD3+/IFN-γ+ pre-enrichment ≥ 0.01% or enrichment of a clear, defined population of ≥10% CD3+/IFN-γ+) with mean pre-enrichment frequencies of CD3+/IFN-γ+ cells of 0.08% (0.01–0.18%), and a mean purity obtained after magnetic enrichment of 44.58% (12.97–76.08%). In case of the remaining n = 4 donors, the enrichment of CD3+/IFN-γ+ T cells was below 10% (mean 5.33%; 3.17–7.62%). These donors did not fulfill the acceptance criteria, hence are not suitable for donation of SARS-CoV-2-specific T cells.

Small-scale T cell products obtained via CSA after magnetic enrichment were further characterized with respect to functionality as defined by activation state (Figure 1E) and expression of cytotoxic molecules (Figure 1F). Compared to the original fraction of unstimulated cells, the enriched T cell
FIGURE 1 | Donor screening and pretesting. (A) Summarized results of donor screening via Interferon-gamma (IFN-γ) Enzyme-Linked ImmunoSpot (ELISpot) assay, n = 198 (all) and n = 104 (responders only) convalescent COVID-19 patients. unstim.: unstimulated control; spw: spots per well. Data are shown as violin plots, each symbol represents data obtained from one donor. ****p < 0.0001; Wilcoxon matched-pairs signed rank test. (B) Representative FACS plots and summarized results from intracellular cytokine staining in whole blood after stimulation with PepTivator SARS-CoV-2 Select using the SARS-CoV-2 T Cell Analysis Kit (Whole Blood) (Miltenyi Biotec). unstim. control: unstimulated control; TNF-α: Tumor Necrosis Factor-alpha. Data are shown as mean of data obtained from n = 12 convalescent COVID-19 patients. (C) Summarized frequencies of IFN-γ-secreting T cell subsets detected and magnetically enriched using Cytokine Secretion Assay (CSA); left: pre- (Continued)
product displayed an activated phenotype as indicated by increased expression of activation-associated surface molecules CD69, CD137, and CD154. Upon storage for 72 h after sample collection, this activated phenotype did not further increase but slightly decrease yet remained at a level higher than observed in preDS, indicating intact T cell functionality up to 72 h after sample collection. Moreover, high expression levels of IFN-γ (mean 279-fold) and granzyme B mRNA (mean 5.2-fold) were detected in the enriched T cell products compared to unstimulated cells, while no difference was observed for perforin mRNA. The increased mRNA expression of IFN-γ and granzyme B was sustained until 72 h after sample collection.

In summary, antiviral T cells reactive against PepTivator SARS-CoV-2 Select were detectable in convalescent COVID-19 patients and these were mainly TNF-α and IFN-γ producing CD8+ and CD4+ T cells. The magnetic enrichment of SARS-CoV2-specific T cells using PepTivator SARS-CoV-2 Select and CSA resulted in T cell products with a mean purity of 44.58% (eligible donors only), an activated phenotype and expression of...
cytotoxic molecules. A positive correlation between results obtained by ELISpot Assay and CSA suggests the suitability of ELISpot Assay for screening of potential donors for antiviral T cell manufacturing (Tischer et al., 2014a). Together, these data give first evidence that the enrichment of SARS-CoV-2-specific T cells for clinical application using PepTivator SARS-CoV-2 Select and the cytokine capture approach is feasible.

Clinical-Grade Manufacturing of SARS-CoV-2 Select-specific T Cells
Based on the results obtained via CSA using PepTivator SARS-CoV-2 Select, clinical-scale manufacturing processes using CliniMACS Prodigy, CCS IFN-gamma and MACS GMP PepTivator SARS-CoV-2 Select were performed. Donors (n = 4) were selected first based on results obtained via ELISpot Assay during donor screening and second based on results of CSA during donor pretesting. SARS-CoV-2-specific T cells responding to MACS GMP SARS-CoV-2 Select could be enriched by 174-fold (Figures 2A,B), resulting in a mean purity of 33.1% (Figure 2C). Clinical-grade manufacturing yielded cell numbers sufficient for the generation of a T cell product containing 5,000 CD3+/IFN-γ+ T cells per kg body weight for a patient with a body weight of up to 154 kg, demonstrating feasibility of SARS-CoV-2-specific T cell manufacturing. Comparison of donor pretesting CSA, clinical grade CCS IFN-gamma and process-accompanying CSA revealed largely similar frequencies of IFN-γ+ T cells both, pre-enrichment, and post-enrichment. In summary, these data show that CSA is currently the most suitable assay for donor selection because it can validly determine the antiviral T cell frequencies and—in contrast to other assays such as intracellular cytokine staining—predict the enrichment efficiency in the production process. Thus, this assay allows the selection of the best possible donor for the patient in that it is very likely that the manufacturing results in a good T cell product with respect to cell numbers and purity (Tischer et al., 2014b).

Analysis of cellular impurities in the DS revealed a decrease of CD3+/IFN-γ- unspecific, potentially alloreactive T cells by 219-fold compared to preDS (Figure 3A). Moreover, innate immune cell subsets were decreased by 108- to 740-fold. Together with the decrease in unspecific CD3+/IFN-γ- cells, frequencies of naïve T cells (T_N) were reduced by 64-fold, while the frequencies of effector memory T cells (T_EM) were markedly increased (Figure 3B). In perspective of clinical application, stability of the T cell product was analyzed (Figure 3C). Viability of the cells and
FIGURE 4 | Cytotoxic potential of clinical-grade SARS-CoV-2-specific T cells (n = 4). SARS-CoV-2-specific T cells obtained by Cytokine Capture System (CCS) and CliniMACS Prodigy were expanded for 7–13 days and subjected to cytotoxicity assays using unloaded and SARS-CoV-2 Select-loaded autologous PBMCs as target cells. (A) Frequencies of cells with active caspase-3/7 or 7-AAD+ cells among target cells (CellTrace Proliferation dye positive). Light bars: unloaded target cells. Dark bars: loaded target cells. Results are displayed as individual results and as means. (B) Cell culture supernatants from cytotoxicity assays from day 12/13 were analyzed with respect to presence of cytotoxic effector molecules by LEGENDPlex Assay. Results are displayed as individual results and as means, n = 4 manufacturing processes. Statistical significance was calculated using Two-way ANOVA and Sidak’s multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
total CD3+ T cell number was unaffected after 72 h of storage at 4°C after end of leukapheresis. The starting material (LP) and the final formulated T cell products (DP) were analyzed with respect to microbial sterility: No growth was observed within 7–14 days of incubation (data not shown). Endotoxin levels were assessed using Endosafe nexgen PTS and were <5 EU/ml (data not shown).

To estimate the reactivity of PepTivator SARS-CoV-2 Select-specific T cells towards the different VOCs, we performed ELISpot assay using peptide pools covering the Spike (S) protein from wild type (WT), and different VOCs as well as membrane (M) and nucleoprotein (N) (Supplementary Figure S1). Samples obtained at the time of leukapheresis (pre-vaccination) and recently collected samples (post-vaccination) were analyzed. All donors had initially been infected early in 2020 and have been vaccinated meanwhile. In accordance with previous reports, frequencies of T cells against M and N proteins slightly decreased throughout the time of convalescence, yet remained detectable (Gussarow et al., 2021). In contrast, T cell frequencies against PepTivator SARS-CoV-2 Select remained stable, suggesting an increased fraction of T cells against the S protein after vaccination. This is supported by the higher frequencies of WT S-specific T cells detected in the samples collected at a later time point. Of note and despite the fact that the donors were infected with the WT and all currently available vaccines are based on the sequences of WT S protein, T cell responses against Delta and Omicron VOCs were detectable both, in samples at the time of leukapheresis (pre-vaccination) as well as in the samples collected at a later time point (post-vaccination). Together, these data indicate that T cells enriched via cytokine capture approach using PepTivator SARS-CoV-2 Select contain T cells reactive against SARS-CoV-2 VOCs.

**DISCUSSION**

SARS-CoV-2-specific T cells developing during infection and subsequent recovery from the disease support viral clearance and control of infection. The developing antiviral T cell repertoire covers a broad range of viral antigens including both, structural and non-structural proteins. COVID-19 patients with insufficient endogenous functional antiviral T cells might benefit from adoptive transfer of SARS-CoV-2-specific T cells isolated from convalescent individuals, a concept which has been developed for viral complications with CMV, ADV, and EBV in immunosuppressed patients after transplantation (Kaeuferle et al., 2019). This study aimed to establish a screening and pretesting strategy to select for potential suitable T cell donors as well as proving feasibility of a rapid clinical-grade SARS-CoV-2-specific T cell enrichment using the CliniMACS Prodigy, CCS IFN-gamma, and MACS GMP PepTivator SARS-CoV-2 Select. In this line, the existing allogeneic T cell registry alloCELL (http://www.alloCELL.org) of the Institute of Transfusion Medicine and Transplant Engineering at Hannover Medical School has been expanded to SARS-CoV-2-specific T cells in donors recovered from SARS-CoV-2 infection. Memory T cell responses against SARS-CoV-2 were quantified and characterized after antigenic restimulation using ELISpot assay, intracellular cytokine staining, and quantitative realtime PCR. Furthermore, in light of clinical-grade manufacturing for adoptive T cell therapy, potential T cell donors were pretested using Cytokine Secretion Assay, largely analogous to the clinical-scale enrichment process via CCS IFN-gamma, and CliniMACS Prodigy. In contrast to ELISpot assay and intracellular cytokine staining, CSA allows for enrichment of antigen-specific T cells secreting IFN-γ upon stimulation. Moreover, frequencies of IFN-γ+ T cells obtained via CSA were comparable to those obtained during clinical-grade manufacturing, demonstrating that CSA is well-suited for selection of potential T cell donors. The four generated clinical-grade T cell products were characterized with respect to their cellular composition as well as to their proliferative and cytotoxic potential by using flow cytometry, in vitro cytotoxicity assays and multiplex analysis. In summary, these data demonstrate that the enriched clinical-grade SARS-CoV-2-specific T cells are able to replicate, specifically recognize and kill target cells, and secrete cytotoxic molecules upon target recognition.

One of the most dreaded side effects of the administration of T cell products is the development of Graft-versus-Host Disease (GvHD) triggered by alloreactive T cells in the product. The presence of naive T cells in T cell products precipitates the risk of GvHD, since naive T cells have a typically broader T cell receptor (TCR) repertoire and, therefore, a higher alloreactivity potential than memory T cell fractions (Nikolich-Zugich et al., 2004; Inman et al., 2018). In a single center dose escalation study in...
Spain, CD45RA-depleted, unselected memory T cells from COVID-19 convalescent donors were given at increasing doses of $1 \times 10^5$, $5 \times 10^5$, and $1 \times 10^6$ memory T cells/kg body weight to hospitalized COVID-19 patients at risk for a severe course (Perez-Martínez et al., 2021; Pérez-Martínez et al., 2021). All three dose levels were tolerated without adverse events. Clinical status of the patients, as assessed by the National Early Warning Score and the 7-point WHO ordinal COVID-19 scale, improved 6 days after application of the Investigational Medicinal Product (IMP). The results from this study suggest that hospitalized COVID-19 patients at risk for a severe course might benefit from adoptive transfer of antiviral memory T cells.

In contrast to CD45RA-depleted memory T cell products, the cellular products generated in this study are specifically enriched for SARS-CoV-2 memory T cells. The recognition of infected cells by enriched antiviral T cells via the corresponding epitopes will lead to the generation and proliferation of endogenous virus-specific T cells in the patient and thus successfully and permanently control the virus. It has recently been shown that third party donor-derived T cells had contributed to endogenous CMV-specific T cell reconstitution in a patient (Neuenhahn et al., 2017; Fabrizio et al., 2021). Therefore, also transferred matched CD4$^+$ T cells harbor the potential to successfully contribute to the elimination of the virus and the infected cells by inducing endogenous CD8$^+$ T cells or vice versa. The effectiveness of CD4$^+$ T cell responses has been demonstrated for AdV (Sester et al., 2002) and polyomavirus BKV (Espada et al., 2020) as well as for SARS-CoV-2 (Grifoni et al., 2020) and is dominated by CD4$^+$ T cells with memory/effector phenotype. On the other hand, the transfer of single-matched HLA-class I-restricted antiviral T cells was sufficient to control CMV infection or reactivation in patients (Uhlin et al., 2012; Grifoni et al., 2020). Antiviral CD4$^+$ and CD8$^+$ T cells recognize virus-infected cells via the presentation of viral peptides in context of HLA class I or II molecules and are activated by interaction of their TCR with the specific peptide/HLA complexes on the virus-infected cells. The antiviral T cells proliferate and CD4$^+$ T cells secrete cytokines in order to support the proliferation and function of CD8$^+$ T cells, thereby contributing to prolonged survival of the adoptively transferred CD8$^+$ T cells (Kaeuferle et al., 2019). The interaction between CD4$^+$ and CD8$^+$ T cell populations is crucial for the elimination of virus-infected cells. Therefore, donor selection for SARS-CoV-2-specific T cell therapy should strongly consider the (partial) match in HLA class I and II alleles of recipient and donor.

Leung and colleagues reported successful manufacturing of SARS-CoV-2-specific T cells from six convalescent COVID-19 patients using CCS IFN-gamma and peptide pools PepTivator SARS-CoV-2 M, N, and S (Leung et al., 2020). They hypothesize that the probability that the recipient will share at least one HLA allele with one of the six donors will be between 88 and 99%, depending on ethnic background. The peptide pool used in this study, PepTivator SARS-CoV-2 Select, consists of 88 peptides with a length of 9–22 amino acids originating from structural and non-structural proteins. Of these, 63 peptides are restricted to HLA class I and 25 peptides are restricted to HLA class II. Overall, the selected peptides allow a broad HLA coverage throughout the Caucasian population and stimulate both, CD4$^+$ and CD8$^+$ T cell subsets. In fact, the HLA-A, -B, and DR alleles represented in the SARS-CoV-2 Select peptide pool are present in $>95\%$, $>85\%$ and $>90\%$ of the donors in the alloCELL registry, respectively. Of note, the majority of these peptides are identical in wild type and currently circulating VOCs, including the Delta and Omicron variants. It is assumed that future emerging VOCs will be sufficiently covered as well by PepTivator SARS-CoV-2 Select. Here, we were able to show that a large fraction of convalescent COVID-19 patients has specific T cells reactive against PepTivator SARS-CoV-2 Select and that these T cells could be magnetically enriched to high purities via IFN-γ CSA.

In large-scale GMP-compliant manufacturing runs using CliniMACS Prodigy, clinical-grade T cells products with purities comparable to those obtained in small-scale donor pretesting were achieved. To minimize the risk of GvHD, the overall T cell dose for adoptive transfer including virus-specific and contaminating T cells should be limited to total 25,000 CD3$^+$ T cells/kg body weight, corresponding to the upper limit of T cells of donor lymphocyte infusion (DLI) in the haploidaligent setting deemed to be safe (Lewalle et al., 2003; Rettinger et al., 2011; Quaiser and Köhl, 2018). Virus-specific T cells manufactured using CliniMACS Prodigy and CCS IFN-gamma enriches for memory T cells and reduces the number of naïve T cells, which could be confirmed by the results of this study. Assuming that naïve T cells are mainly responsible for GvHD, enrichment of antiviral T cells by IFN-γ secretion will significantly lower GvHD risk while preserving immune memory against viral infections (Teschner et al., 2014; Bleakley et al., 2014; Bleakley et al., 2022). This is further supported by two literature reports (Feuchtlinger et al., 2006; Aissi-Rothé et al., 2010) showing that enrichment for virus-specific T cells reduced proliferation stimulated by a mixed lymphocyte culture with HLA mismatched PBMCs by one to two logs compared with the original lymphocyte harvest. While COVID-19 patients may be less prone to GvHD as they are not fully immunodeficient, on the other hand they may be more prone to GvHD as they have a hyperinflammatory milieu (García, 2020). Hence, for safety reasons a dose finding study seems advisable. In this regard, a total CD3$^+$ T cell dose of no more than 25,000 cells per kg body weight is 4- to 40-times lower than the CD45RA-depleted memory T cells from COVID-19 convalescent donors applied in the single center dose escalation study, where no toxicities or adverse events were observed (Pérez-Martínez et al., 2021). In contrast to CD45RA-depleted memory T cell products, the cellular products generated in this study are enriched for SARS-CoV-2 memory T cells, therefore resulting in a product specific for COVID-19 patients. In the four manufacturing processes performed in this study, on average cell numbers sufficient for treatment of a patient of 154 kg body weight receiving a dose of 5,000 CD3$^+$/IFN-γ$^+$ cells per kg body weight and without exceeding the limit of 25,000 total CD3$^+$ T cells per kg body weight were obtained. Moreover, the antiviral T cells were able to proliferate and specifically recognize target cells presenting SARS-CoV-2-specific peptides. Recognition of target cells resulted in secretion of cytotoxic molecules as well as induction of caspase activity and cells death of target cells. Therefore, the adoptively transferred enriched antiviral T cells
are expected to be more efficient in clearance of the SARS-CoV-2 infection compared to CD45RA-depleted memory T cells. The target population for the first phase I clinical trial in Germany (ClinicalTrials.gov Identifier: NCT04762186) are patients with COVID-19, WHO clinical progression scale 4 with predefined risk factors for a severe disease course or patients with WHO clinical progression scale 5 (WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection, 2020).

CONCLUSION

The cellular immune response against SARS-CoV-2 is characterized by antiviral T cells with a broad repertoire, remaining readily detectable more than 1 year after initial infection. In contrast to antibody generation the protective effect of this T cell response is largely maintained also towards viral VOCs. Immunodeficient individuals or COVID-19 patients with insufficient endogenous T cell responses might therefore benefit from adoptive transfer of allogeneic, SARS-CoV-2-specific T cells isolated from convalescent individuals. In the present study, we have shown that PepTivator SARS-CoV-2 Select covering a broad variety of structural and non-structural SARS-CoV-2 proteins is suitable for donor selection and subsequent clinical-scale manufacturing of SARS-CoV-2-specific T cells. We performed four successful clinical-grade manufacturing processes for the generation of SARS-CoV-2-specific T cell products for adoptive T cell therapy. Enriched SARS-CoV-2-specific T cells harbored proliferative capacity and cytotoxic potential towards their target cells. By enriching for antiviral memory T cells with depletion of potentially alloreactive naïve T cells and careful consideration of partial HLA class I and II matching between donor and recipient, adoptive transfer of SARS-CoV-2-specific T cells should provide a unique and safe treatment option for COVID-19 patients at risk for a severe course of the disease.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Internal Review Board of Hannover Medical School, Hannover, Germany. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

AB—data acquisition, analysis, writing, final approval; ST-Z—data acquisition, analysis, writing, final approval; MS—data acquisition, analysis, final approval; PM—data acquisition, analysis, final approval; JS—data acquisition, analysis, final approval; SK—data acquisition, analysis, final approval; JB-B—analysis, writing, final approval; NG—donor recruitment, donor information, final approval; JM—donor recruitment, donor information, final approval; LG—donor recruitment, donor information, final approval; MV—HLA typing, final approval; JW—clinical background, final approval; BM-K—clinical background, final approval; HB—clinical background, final approval; CC—technical support, final approval; OB—technical support, analysis, final approval; MS—technical support, final approval; PL—manufacturing background, final approval; OC—clinical background, final approval; MH—clinical background, final approval; RB—donor recruitment, final approval; DS—technical support, final approval; PK—clinical background, final approval; BE-V—study design, analysis, writing, final approval.

FUNDING

This study was in part funded by the state of North Rhine-Westphalia. The authors declare that this study received funding from the Ministry of Economy, Innovation, Digitalization and Energy at the State of North Rhine Westphalia. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

ACKNOWLEDGMENTS

The authors wish to thank Nicole Neumann, Dörthe Rokitta, Sarina Lukis, Juliane Ebersold, Daniel Gussarow, and Nadine Maronn for technical support.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fbioe.2022.867042/full#supplementary-material

REFERENCES

Aïssi-Rothé, L., Decot, V., Venard, V., Jeulin, H., Salmon, A., Clement, L., et al. (2010). Rapid Generation of Full Clinical-Grade Human Antiadenovirus Cytotoxic T Cells for Adoptive Immunotherapy. J. Immunother. 33, 414–424. doi:10.1097/cji.0b013e3181cc263b

Bacher, P., Rosati, E., Esser, D., Martini, G. R., Saggau, C., Schiminsky, E., et al. (2020). Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. Immunity 53, 1258–1271. doi:10.1016/j.immuni.2020.11.016

Bergamaschi, L., Mescia, F., Turner, L., Hanson, A. L., Kotagiri, P., Dunmore, B. J., et al. (2021). Longitudinal Analysis Reveals that Delayed Bystander CD8+ T Cell Activation and Early Immune Pathology Distinguish Severe Covid-19 from
Borobia, A. M., et al. (2021). A Phase I/ii Dose-Escalation Single center Study to Evaluate the Safety of Infusion of Memory T Cells as Adoptive Therapy in Patients with COVID-19 Disease and Unexposed Individuals. Cell 181, 1489–1501. doi:10.1016/j.cell.2020.05.015

Gussarow, D., Bonifacius, A., Cossmann, A., Stankov, M. V., Mausberg, P., Tischer-Zimmermann, S., et al. (2021). Long-lasing Immunity against Sars-CoV-2: Dream or Reality? Front. Med. 8, 770381. doi:10.3389/fmed.2021.770381

Hanley, R., Rousso, C. A., Osborn, M., and Naresh, K. N. (2020). Convalescent Donor SARS-CoV-2-specific Cytotoxic T Lymphocyte Infusion as a Possible Treatment Option for COVID-19 Patients with Severe Disease Has Not Received Enough Attention till Date. Br. J. Haematol. 189, 1062–1063. doi:10.1111/bjh.16780

He, L., Zhang, Q., Zhang, Y., Fan, Y., Yuan, F., and Li, S. (2021). Single-cell Analysis Reveals Cell Communication Triggered by Macrophages Associated with the Reduction and Exhaustion of CD8+ T Cells in COVID-19. Cell Commum Signal 19, 73. doi:10.18632/oncotarget.20019

Hofnberg, S., Möhn, N., Eiz-Vespres, B., Maerker-Kolhoff, B., Gottlieb, J., Blaszczyk, R., et al. (2021). Allogeneic Bk Virus-specific T Cell Treatment in 2 Patients with Progressive Multifocal Leuкоencephalopathy. Neurology Neuroimmunol Neuroinflammation 8, 4. doi:10.1212/NXI.0000000000001020

Inman, C. F., Eldershaw, S. A., Coudacque, J. E., Davies, N. J., Sharma-Oates, A., Rai, T., et al. (2018). Unique Features and Clinical Importance of Acute Alloreactive Donor Responses. JCI Insight 3, e97219. doi:10.1172/jci.insight.97219

Jarjour, N. N., Masopust, D., and Jameson, S. C. (2021). T Cell Memory: Understanding Covid-19. Immunity 54, 14–18. doi:10.1016/j.immuni.2020.12.009

Kauffefer, T., Krauss, R., Blaeschke, F., Willer, S., and Feuchtiger, T. (2019). Strategies of Adoptive T-cell transfer to Treat Refractory Viral Infections post Allogeneic Stem Cell Transplantation. J. Hematol. Oncol. 12, 13. doi:10.1186/s11188-019-0707-1

Kong, M., Zhang, H., Cao, X., Mao, X., and Lu, Z. (2020). Higher Level of Neutrophil-to-Lymphocyte Ratio is Associated with Severe Covid-19. Epidemiol. Infect. 148, e139. doi:10.1017/S0950268820001557

Le Bert, N., Clapham, H. E., Tan, A. T., Chia, W. N., Tham, C. Y. L., Lim, J. M., et al. (2021). Highly Functional Virus-specific Cellular Immune Response in Asymptomatic Sars-CoV-2 Infection. J. Exp. Med. 218, 218. doi:10.1084/jem.20202617

Leung, W., Soh, T. G., Linn, Y. C., Low, J. G., Loh, J., Lim, J. M., et al. (2020). Rapid Production of Clinical-grade SARS-CoV-2 Specific T Cells. Adv. Cell Gene Ther. 3, e101. doi:10.1002/acg2.101

Leuwel, P., Trillet, A., Delforge, A., Cermbez, P., Selleslag, D., De Muynck, H., et al. (2003). Donor Lymphocyte Infusions in Adult Haploidentical Transplant: A Dose Finding Study. Bone Marrow Transpl. 31, 39–44. doi:10.1038/sj.bmt.1703779

Liu, J., Liu, Y., Xiang, P., Pu, L., Xiong, H., Li, C. L., et al. (2020). Neutrophil-to-lymphocyte Ratio Predicts Critical Illness Patients with 2019 Coronavirus Disease in the Early Stage. J. Transl. Med. 18, 206. doi:10.1186/s12967-020-02374-0

Marcotte, H., Piralla, A., Zuo, F., Du, L., Cassaniti, I., Wan, H., et al. (2022). Immunity to Sars-CoV-2 up to 15 Months after Infection. Science 25, 1035. doi:10.1126/science.abc2.101

Mutfuoglu, M., Olson, A., Marin, D., Ahmed, S., Mulanovich, V., Tumulsa, S., et al. (2018). Allogeneic Bk Virus-specific T Cells for Progressive Multifocal Leuкоencephalopathy. N. Engl. J. Med. 379, 1443–1451. doi:10.1056/ nejmoa1801540

Neuhahen, N., Albrecht, J., Ondendahl, M., Schlott, F., Dössinger, G., Schieman, M., et al. (2017). Transfer of Minimally Manipulated Cmv-specific T Cells from Stem Cell or Third-party Donors to Treat Cmv Infection after Allo-hsct. Leukemia 31, 2161–2171. doi:10.1038/leu.2017.16

Nikolich-Zugich, J., Slika, M. K., and Messaoudi, I. (2004). The Many Important Faces of T-cell Repertoire Diversity. Nat. Rev. Immunol. 4, 123–132. doi:10.1038/nri1292

Peng, Y., Menterz, A. J., Liu, G., Yao, X., Yin, Z., Dong, D., et al. (2020). Broad and strong Memory Cd4+ and Cd8+ T Cells Induced by Sars-CoV-2 in uk Convalescent Covid-19 Patients. bioRxiv 21, 1336–1345. doi:10.1101/2020.02.072-6

Perez-Martinez, A., Ferreras, M., Guerra, P., Pascual-Miguel, B., Mestre-Durán, C., Borobia, A. M., et al. (2021). A Phase I/ii Dose-escalation single center Study to Evaluate the Safety of Infusion of Memory T Cells as Adoptive Therapy in
Coronavirus Pneumonia and/or Lymphopenia (Release). Cytotherapy 23, S29. doi:10.1016/s1465324921002905

Pérez-Martínez, A., Mora-Rillo, M., Ferreras, C., Guerra-García, P., Pascual-Miguel, B., Mestre-Durán, C., et al. (2021). Phase I Dose-Escalation Single centre Clinical Trial to Evaluate the Safety of Infusion of Memory T Cells as Adoptive Therapy in Covid-19 (Release). EClinicalMedicine 39, 101086. doi:10.1016/j.eclinm.2021.101086

Pilz, S. T.-S., Trummer, C., Krause, R., and Ioannidis, J. P. A. (2022). Sars-cov-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity. January 10, 2022. doi:10.1016/j.envres.2022.112911

Quaiser, A., and Köhl, U. (2018). Was ist gesichert bei den Zelltherapien? Frontiers in Bioengineering and Biotechnology | www.frontiersin.org April 2022 | Volume 10 | Article 867042

Bonifacius et al. SARS-CoV-2-Specific T Cells. 2020. doi:10.1016/j.eclinm.2021.101086

Pérez-Martínez, A., Mora-Rillo, M., Ferreras, C., Guerra-García, P., Pascual-Miguel, B., Mestre-Durán, C., et al. (2021). Phase I Dose-Escalation Single centre Clinical Trial to Evaluate the Safety of Infusion of Memory T Cells as Adoptive Therapy in Covid-19 (Release). EClinicalMedicine 39, 101086. doi:10.1016/j.eclinm.2021.101086

Pilz, S. T.-S., Trummer, C., Krause, R., and Ioannidis, J. P. A. (2022). Sars-cov-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity. January 10, 2022. doi:10.1016/j.envres.2022.112911

Quaiser, A., and Köhl, U. (2018). Was ist gesichert bei den Zelltherapien? Frontiers in Bioengineering and Biotechnology | www.frontiersin.org April 2022 | Volume 10 | Article 867042

Pérez-Martínez, A., Mora-Rillo, M., Ferreras, C., Guerra-García, P., Pascual-Miguel, B., Mestre-Durán, C., et al. (2021). Phase I Dose-Escalation Single centre Clinical Trial to Evaluate the Safety of Infusion of Memory T Cells as Adoptive Therapy in Covid-19 (Release). EClinicalMedicine 39, 101086. doi:10.1016/j.eclinm.2021.101086

Pilz, S. T.-S., Trummer, C., Krause, R., and Ioannidis, J. P. A. (2022). Sars-cov-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity. January 10, 2022. doi:10.1016/j.envres.2022.112911

Quaiser, A., and Köhl, U. (2018). Was ist gesichert bei den Zelltherapien? Frontiers in Bioengineering and Biotechnology | www.frontiersin.org April 2022 | Volume 10 | Article 867042

World Health Organisation (2021). Sars-cov-2 Variant – united kingdom of Great Britain and Northern Ireland. AvailableAt: https://www.who.int/csr/don/21-december-2020-sars-cov-2-variant-united-kingdom/en/ (15.03.2021).

Conflict of Interest: OAC reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, and Scynexis; Consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paretik, PSI, Shionogi; A patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); Other interests from DGHQ, DGI, ECMM, ISHAM, MSG-ERC, and Wiley. PK reports grants or contracts from German Federal Ministry of Research and Education (BMBF) B-FAST (Bundesweites Forschungszentrum Angewandte Surveillance und Testing) and NAPKON (Nationales Pandemie Kohorten Netz, German National Pandemic Cohort Network) of the Network University Medicine (NUM) and the State of North Rhine-Westphalia; Consulting fees from Ambu GmbH, Gilead Sciences, Mundipharma Research Limited, Noxxon N.V. and Pfizer Pharma; Honoraria for lectures from Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, BioRad Laboratories Inc., European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Russelsheim, medupdate GmbH, MedMedia, MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Scilink Comunicación Científica SC and University Hospital and LMU Munich; Participation on an Advisory Board from Ambu GmbH, Gilead Sciences, Mundipharma Research Limited and Pfizer Pharma; A pending patent currently reviewed at the German Patent and Trade Mark Office; Other non-financial interests from Elsevier, Wiley and Taylor & Francis online outside the submitted work. Authors HB, CC, OB, and MS are employed by the company Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany. Author DS is employed by the company Miltenyi Biomedicine GmbH, Bergisch Gladbach, Germany.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Bonifacius, Tischer-Zimmermann, Santamorena, Maussberg, Schenk, Koch, Barnstorf-Brande, Gödecke, Martens, Goudova, Verboom, Wittig, Maechler-Kolhoff, Baumann, Clark, Bruns, Simon, Lang, Cornel, Hallek, Blaszyk, Seiflering, Köhler and Eiz-Vesper. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.